LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

50.86 -0.25

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

50.58

Max

51.19

Galvenie mērījumi
By Trading Economics
Ienākumi	-68M -45M
Pārdošana	27M 192M
P/E Sektora vidējais	48.435 110.024
Peļņas marža	-23.486
Darbinieki	674
EBITDA	-75M -37M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+21.12% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 24. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-208M 2.9B
Iepriekšējā atvēršanas cena	51.11
Iepriekšējā slēgšanas cena	50.86

Ziņu noskaņojums

By Acuity

12%

88%

15 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

31.35 / 32.36 Atbalsts un pretestība

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. febr. 17:37 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

2026. g. 20. febr. 16:18 UTC

Galvenie tirgus virzītāji

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

2026. g. 20. febr. 23:12 UTC

Iegādes, apvienošanās, pārņemšana

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026. g. 20. febr. 22:12 UTC

Peļņas

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 20. febr. 21:23 UTC

Peļņas

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026. g. 20. febr. 21:20 UTC

Tirgus saruna

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026. g. 20. febr. 21:01 UTC

Iegādes, apvienošanās, pārņemšana

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026. g. 20. febr. 20:38 UTC

Tirgus saruna

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

2026. g. 20. febr. 20:17 UTC

Tirgus saruna

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

2026. g. 20. febr. 20:11 UTC

Tirgus saruna

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

2026. g. 20. febr. 19:59 UTC

Tirgus saruna

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

2026. g. 20. febr. 19:58 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

2026. g. 20. febr. 19:49 UTC

Tirgus saruna

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

2026. g. 20. febr. 19:09 UTC

Tirgus saruna

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

2026. g. 20. febr. 19:00 UTC

Tirgus saruna

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

2026. g. 20. febr. 18:28 UTC

Tirgus saruna

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

2026. g. 20. febr. 18:20 UTC

Tirgus saruna

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

2026. g. 20. febr. 18:05 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 20. febr. 18:04 UTC

Tirgus saruna

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

2026. g. 20. febr. 17:38 UTC

Tirgus saruna

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

2026. g. 20. febr. 17:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. febr. 17:24 UTC

Tirgus saruna

Correction to Treasury Yields Fall Market Talk

2026. g. 20. febr. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 20. febr. 16:53 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 20. febr. 16:53 UTC

Tirgus saruna

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

2026. g. 20. febr. 16:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. febr. 16:45 UTC

Tirgus saruna

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

2026. g. 20. febr. 16:40 UTC

Tirgus saruna

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

21.12% augšup

Prognoze 12 mēnešiem

Vidējais 61.6 USD 21.12%

Augstākais 65 USD

Zemākais 55 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

15 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.